Trial Profile
A Phase 1 Study of Blinatumomab in Combination With Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients With Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Acute biphenotypic leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition, based on safety and efficacy data, blina + nivo was expanded to include 6 additional pts without additional DLTs. Ongoing analyses of changes in T cell subpopulations, co-signaling molecule expression, and single cell RNA seq results will be presented.
- 12 Dec 2023 Results reporting efficacy and safety data presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 08 Sep 2023 Planned End Date changed from 5 Nov 2023 to 6 Sep 2024.